SNBP - Sun BioPharma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
5.0000
+0.2500 (+5.26%)
At close: 3:40PM EDT
Stock chart is not supported by your current browser
Previous Close4.7500
Open5.2500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range5.0000 - 5.2500
52 Week Range2.0000 - 5.2500
Volume800
Avg. Volume337
Market Cap28.61M
Beta (3Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-1.0870
Earnings DateAug 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Sun BioPharma, Inc. Provides a Business Update and Files Report for Q2 2019

    Enrollment in Third Cohort of PDA Combination Study is Encouraging                              Preliminary Efficacy Signals Improve with New Data Regarding Second CohortEntire.

  • GlobeNewswire

    Sun BioPharma, Inc. Provides an Update on Ongoing Front-line Pancreatic Cancer Clinical Trial

    Sun BioPharma, Inc. (SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides an update on the Company’s current clinical trial. Following successful conclusion of the first SBP-101 dose escalation study in heavily pretreated pancreatic cancer patients that showed SBP-101 could be administered safely as monotherapy, a second Phase 1 safety study entitled, “SBP-101 Administered in Combination with Gemcitabine and Nab-paclitaxel in Newly Diagnosed Patients with Metastatic Pancreatic Ductal Adenocarcinoma” was undertaken to evaluate the addition of SBP-101 to front line gemcitabine and nab-paclitaxel treatment.

  • GlobeNewswire

    Sun BioPharma, Inc. Provides a Business Update and Files Report for Q1 2019

    Enrollment in Second Cohort of PDA Combination Study CompletedNew Funding Totaling $0.8 Million Secured MINNEAPOLIS, May 14, 2019 -- Sun BioPharma, Inc. (OTCQB:SNBP), a.

  • GlobeNewswire

    Sun BioPharma Provides Business Update and Files Annual Report for 2018

    Front-Line Combination Study with Gemcitabine and Nab-Paclitaxel enrolling second Cohort of Phase 1a Company reinstates founder and Executive Chairman, Dr. Michael Cullen as.

  • GlobeNewswire

    Sun BioPharma, Inc. Provides a Business Update and Files Report for Q3 2018

    Sun BioPharma, Inc. opens third site in Melbourne, Australia in Front-Line Combination Study of SBP-101 with Gemcitabine and nab-Paclitaxel for the Treatment of Patients with.

  • GlobeNewswire

    Sun BioPharma, Inc. to Present Results of New Pancreatitis Study at American Pancreatic Association Meeting in Miami Beach, FL

    Sun BioPharma, Inc. (SNBP), a clinical stage biopharmaceutical company specializing in disruptive therapeutics for pancreatic diseases, announced today that they will present results of a new study entitled “Effect of SBP-101 in a Mouse Model of Cerulein-induced Acute Pancreatitis” at the American Pancreatic Association meeting in Miami, FL on Nov. 1. The study, performed in collaboration with Cedars-Sinai Medical Center in Los Angeles, CA and funded by the National Institutes of Health, evaluated the ability of SBP-101, a polyamine metabolic inhibitor (PMI), to impact the development of acute pancreatitis using different formulations and dosing regimens.

  • GlobeNewswire

    Sun BioPharma, Inc. Announces Leadership Changes

    Sun BioPharma, Inc. (SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today announces leadership changes in the organization. Effective October 31, 2018, David B. Kaysen is stepping down as President, CEO and Board member of Sun BioPharma, Inc. and its wholly owned subsidiary, Sun BioPharma Australia Pty Ltd.  Also, effective October 31, 2018, Michael T. Cullen, MD, MBA, the company’s Executive Chairman, has accepted the additional responsibilities of President and CEO of Sun BioPharma, Inc. and its wholly owned subsidiary, Sun BioPharma Australia Pty Ltd.